Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Ribociclib and Endocrine Therapy as Adjuvant Treatment in HR+/HER2− Early Breast Cancer
- ASCO 2023: Abstract Recommendations From Dr. Lee Schwartzberg for Breast Cancer
- 2022 Top Story in Oncology: DESTINY-Breast04 — Trastuzumab Deruxtecan for HER2-Low Breast Cancer
- ctDNA Mutation Tracking to Detect MRD and Trigger Intervention in Patients With Moderate- and High-Risk Early-Stage TNBC
- Overall Survival Outcomes Following Adjuvant Olaparib Therapy in Patients With Germline Pathogenic Variants in BRCA1/2 and High-Risk Early Breast Cancer
- Patient-Reported Outcomes of Trastuzumab Deruxtecan vs Treatment of Physician's Choice in HER2-Low MBC
- ESMO 2022: Recommendations From Dr. Lee Schwartzberg for Breast Cancer
- Neoadjuvant Endocrine Therapy for Strongly HR-Positive and HER2-Negative Early Breast Cancer
- Comparable Effectiveness of 45- and 20-Minute Post-Infusion Scalp Cooling Time in Preventing Paclitaxel-Induced Alopecia
- Fracture Reduction and Survival Outcomes With Adjuvant Denosumab in Breast Cancer